Patents by Inventor Joseph A. Kovacs
Joseph A. Kovacs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080204538Abstract: Methods and devices for forming, such as by printing, high quality, high throughput, ultraviolet curable gel ink images on corrugated substrates for packaging applications are disclosed. The methods and devices have excellent edge acuity and do not require precoating of the substrate prior to printing or nitrogen inerting during curing.Type: ApplicationFiled: April 22, 2008Publication date: August 28, 2008Applicant: XEROX CORPORATIONInventors: Gregory Joseph Kovacs, Steven E. Ready, Jennifer L. Belelie, Peter Gordon Odell, Mojgan Rabbani, Shriram V. Revankar
-
Patent number: 7379771Abstract: A system comprising an implantable medical device includes a ventricular heart signal sensing circuit, a pacing therapy circuit, and a controller circuit coupled to the signal sensing circuit and the therapy circuit. The controller circuit is operable to detect a ventricular tachycardia heart rhythm from the cardiac signal, measure an amount of time the heart signal is one of inside or outside of an effective amplitude band, and initiate ATP therapy if the measured amount of time is less than a threshold amount of time.Type: GrantFiled: November 1, 2004Date of Patent: May 27, 2008Assignee: Cardiac Pacemakers, Inc.Inventors: Joseph Kovac, Julie Thompson
-
Publication number: 20060292317Abstract: Disclosed is a multilayer article which includes an ink jet recordable substrate at least partially connected to a substantially nonporous material. The ink jet recordable substrate is at least partially coated with a substantially water-resistant coating composition. Also at least one of the ink jet recordable substrate and the substantially nonporous material is at least partially coated with a friction-reducing coating composition.Type: ApplicationFiled: August 31, 2006Publication date: December 28, 2006Inventors: Luciano Parrinello, Randall Rogers, Charles Hill, Larry Lipko, Paul Benenati, Peter Nowakowski, Joseph Kovacs, Charles Kahle
-
Publication number: 20060292318Abstract: A coated ink recordable substrate prepared by providing an ink recordable substrate having a top surface and a bottom surface; providing a coating composition having a pH less than 7 including (i) an aqueous polyurethane dispersion and (ii) an aqueous solution of a nitrogen-containing polymeric dye fixative; and applying the coating composition to at least one side of the ink recordable substrate.Type: ApplicationFiled: August 31, 2006Publication date: December 28, 2006Inventors: Luciano Parrinello, Randall Rogers, Charles Hill, Larry Lipko, Paul Benenati, Peter Nowakowski, Joseph Kovacs, Charles Kahle
-
Publication number: 20060095084Abstract: A system comprising an implantable medical device includes a ventricular heart signal sensing circuit, a pacing therapy circuit, and a controller circuit coupled to the signal sensing circuit and the therapy circuit. The controller circuit is operable to detect a ventricular tachycardia heart rhythm from the cardiac signal, measure an amount of time the heart signal is outside of an effective amplitude band, and initiate ATP therapy if the measured amount of time is less than a threshold amount of time.Type: ApplicationFiled: November 1, 2004Publication date: May 4, 2006Inventors: Joseph Kovac, Julie Thompson
-
Publication number: 20040043409Abstract: Particularly sensitive techniques for the detection of P. carinii in clinical samples are disclosed. These techniques relate to the PCR amplification and/or detection of human-P. carinii major surface glycoprotein (MSG) gene sequences. Also disclosed are seven novel genes encoding human-P. carinii MSG, and the proteins encoded for by these genes. These genes provide proof that human-P. carinii MSG is encoded for by a highly conserved gene family, and that the corresponding proteins have a very highly conserved region of about 100 amino acids near their C-terminal end. This highly conserved carboxy-terminal region has a significantly different sequence than that found in rat-derived MSG.Type: ApplicationFiled: September 2, 2003Publication date: March 4, 2004Applicant: The Government of the USA represented by Secretary of the Department of Health & Human ServicesInventors: Joseph A. Kovacs, Shengning Huang, Henry Masur, Steven H. Fischer, Vee J. Gill, Qin Mei
-
Patent number: 6664053Abstract: Particularly sensitive techniques for the detection of P. carinii in clinical samples are disclosed. These techniques relate to the PCR amplification and/or detection of human-P. carinii major surface glycoprotein (MSG) gene sequences. Also disclosed are seven novel genes encoding human-P. carinii MSG, and the proteins encoded for by these genes. These genes provide proof that human-P. carinii MSG is encoded for by a highly conserved gene family, and that the conesponding proteins have a very highly conserved region of about 100 amino acids near their C-terminal end. This highly conserved carboxy-terminal region has a significantly different sequence than that found in rat-derived MSG.Type: GrantFiled: February 9, 2001Date of Patent: December 16, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joseph A. Kovacs, Shengning Huang, Henry Masur, Steven H. Fischer, Vee J. Gill, Qin Mei
-
Publication number: 20030180254Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.Type: ApplicationFiled: January 23, 2003Publication date: September 25, 2003Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human ServicesInventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
-
Patent number: 6548055Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.Type: GrantFiled: August 9, 2000Date of Patent: April 15, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
-
Patent number: 6190656Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.Type: GrantFiled: September 2, 1997Date of Patent: February 20, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
-
Patent number: 5845643Abstract: An arm board and method of using the same for positioning and restraining the forearm and hand of a patient to receive either an intravenous or intra-arterial line. An elongated malleable core member is provided with padding on at least one surface, the core member having an adjustable bending point along the length with the member capable of nonpermanently bending at the bending point from a flat configuration to an angled configuration. A pair of adjustable straps secure the patient's hand and forearm to the core member.Type: GrantFiled: June 5, 1996Date of Patent: December 8, 1998Assignee: Dale Medical Products, Inc.Inventors: Egidia M. Vergano, Joseph Kovacs
-
Patent number: 5696079Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.Type: GrantFiled: May 26, 1995Date of Patent: December 9, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci
-
Patent number: 5487894Abstract: A dietary supplement composition is disclosed which contains dehydrated mung bean sprout and beta-glucan enriched oat groat.Type: GrantFiled: December 19, 1994Date of Patent: January 30, 1996Inventor: Joseph Kovacs
-
Patent number: 5419900Abstract: A method for activating a mammalian immune system entails a series of continuous IL-2 infusions that are effected intermittently over an extended period. For example, IL-2 can be administered continuously for a period that is on the order of 5 days in length, and successive infusions of this nature can be separated by a period of at least 4 weeks. Sustained beneficial effects, including elevated CD4 cell counts, restoration of lymphocyte function and an increase in the number of IL-2 receptors, are achieved with such intermittent IL-2 therapy, which can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha.Type: GrantFiled: May 19, 1993Date of Patent: May 30, 1995Assignee: The United States of America as represented by the Department of of Health and Human ServicesInventors: H. Clifford Lane, Joseph A. Kovacs
-
Patent number: 5246833Abstract: Hybridomas producing antibodies having specific binding affinity against Pneumocystis carinii have been obtained and a method and kit for detecting P. carinii infection in humans have been described.Type: GrantFiled: May 4, 1990Date of Patent: September 21, 1993Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Joseph A. Kovacs, Henry Masur
-
Patent number: 5068253Abstract: The present invention relates to a method of treating or preventing a microbial infection, such as Pneumocystis carinii or Toxoplasma gondii, in a patient comprising administering to the patient an antimicrobially effective amount of p-acetamidobenzoic acid or a pharmaceutically acceptable salt thereof so that the microbial infection is inhibited. P-acetamidobenzoic acid or an acceptable salt thereof can be used to treat infections caused by Pneumocystis carinii, Toxoplasma gondii, Plasmodium species and other microorganisms containing the enzyme dihydropteroate synthetase such as most bacteria and some yeasts. The method of the present invention is particularly applicable in situations where the patient is immunosuppressed.Type: GrantFiled: July 11, 1990Date of Patent: November 26, 1991Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joseph Kovacs, Henry Masur, Carmen Allegra
-
Patent number: 4925800Abstract: Hybridomas producing antibodies having specific binding affinity against Pneumocystis carinii having been obtained and a method and kit for detecting P. carinii infection in humans having been described.Type: GrantFiled: December 4, 1986Date of Patent: May 15, 1990Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joseph A. Kovacs, Henry Masur
-
Patent number: 4886665Abstract: A food supplement composition is described containing an oat extract and an extract of nettle (Urtica). The combined extracts can be in the form of powder which is added to a beverage or any fruit juice to provide a nutritional drink. The composition can also be used for the treatment of a dysfunction of a warm blooded mammal. The products can be taken in various forms such as dried powdered mix with a liquid, as a pill, tablet, capsule, or for nasal delivery.Type: GrantFiled: March 11, 1987Date of Patent: December 12, 1989Assignee: Arcopharma Ltd.Inventor: Joseph Kovacs
-
Patent number: 4694007Abstract: A method of treating infections of Toxoplasmosis or P. carini comprising administering to the host an effective amount of trimetrexate, (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline.Type: GrantFiled: May 20, 1986Date of Patent: September 15, 1987Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Carmen Allegra, James C. Drake, Bruce A. Chabner, Henry Masur, Joseph A. Kovacs
-
Patent number: 4445894Abstract: A band for securing a catheter or similar device to a limb of a human comprising a stretchable primary strap adapted to encircle a limb. A part of the strap is made of a soft looped fabric and the strap also carries a male Velcro-type fastening material which cooperates with the looped fabric to enable the strap to be secured in place about the limb. A secondary strap made of a flexible material is secured, hooks up, intermediate its ends to the central portion of the primary strap on the looped fabric. The secondary strap is made of a male Velcro-type fastening material, and each end of the secondary strap is designed to be looped over and encircle the catheter or similar device and attach to the looped fabric to hold the catheter or similar device securely in place on the limb.Type: GrantFiled: August 12, 1982Date of Patent: May 1, 1984Assignee: Baka Manufacturing Company, Inc.Inventor: Joseph Kovacs